Contamin
Christian Contamin, Le Plantay FR
Patent application number | Description | Published |
---|---|---|
20090135665 | CONCRETE PRODUCTION PLANT - The present disclosure allows concrete to be produced on the work site, as and when required, and to limit the space occupied by the production plant. | 05-28-2009 |
Henri Contamin, Marlieux FR
Patent application number | Description | Published |
---|---|---|
20090135665 | CONCRETE PRODUCTION PLANT - The present disclosure allows concrete to be produced on the work site, as and when required, and to limit the space occupied by the production plant. | 05-28-2009 |
Pauline Contamin, Magny En Vexin FR
Patent application number | Description | Published |
---|---|---|
20110015205 | Trazodone Composition for Once a Day Administration - The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders. | 01-20-2011 |
20110021535 | Trazodone Composition for Once a Day Administration - The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders. | 01-27-2011 |
20110027370 | Sustained Drug Release Composition - The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent. | 02-03-2011 |
20110033537 | Sustained Drug Release Composition - The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent. | 02-10-2011 |
Pauline Contamin, La Feuillie FR
Patent application number | Description | Published |
---|---|---|
20130098286 | METHOD AND AGENT FOR DETECTING DRUGS IN BEVERAGES - The present invention relates to a method for combating chemical submission, which comprises: putting into solution, in a beverage, a pharmaceutical form comprising an active ingredient and at least 0.05 mg, preferably from 0.2 to 5 mg, even more preferentially from 0.3 to 2 mg of at least one water-soluble colouring agent chosen from: indigocarmine or E 132, erythrosine or E 127, brilliant blue FCF, alphazurine FG, fast green FCF, quinzarine green SS, orange II, tartrazine and Sunset yellow FCF, detecting the pharmaceutical form, said detection being characterized by the immediate change in colour of the beverage; it also relates to the use of said colorant for combating chemical submission, and also to a non-film-coated solid pharmaceutical form comprising said colorant. | 04-25-2013 |
20130108556 | PHARMACEUTICAL FORM FOR COMBATING CHEMICAL SUBMISSION OF A MEDICAMENT | 05-02-2013 |
20140322321 | TABLET CAPABLE OF COMBATTING MISUSE BY INJECTION - The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection. | 10-30-2014 |